ITMN shares plummeted after the biotech said late Tuesday the Food and Drug Administration needs more data to approve its lung treatment. In March, an advisory panel to the FDA recommended in a 9 to 3 vote that the agency approve Esbriet, a treatment for idiopathic pulmonary fibrosis, an ultimately fatal disease where inflamed lung tissue can no longer process oxygen. InterMune said it will meet as soon as possible with the FDA, which said it needs another clinical trial on the drug. InterMune shares plummeted 79% to $9.59 in after-hours activity. http://www.marketwatch.com/story/intermune-drops-after-fda-fails-to-clear-lung-drug-2010-05-04 Outsch.